What question did this study set out to answer?

This study aims to assess the pharmacodynamic effects of KN057 in patients with haemophilia or von Willebrand disease type 3.

June 6, 2026Haemophilia

An Ex Vivo Pharmacodynamic Study of KN057, a Tissue Factor Pathway Inhibitor Neutralizing Antibody, in Plasma Samples From Patients With Haemophilia or VWD3

View Full Paper

Ask AI

Bookmark

Authors

Ex vivo study evaluates KN057's effects on coagulation in haemophilia and VWD3 patients, suggesting potential benefits.

This study aims to assess the pharmacodynamic effects of KN057 in patients with haemophilia or von Willebrand disease type 3.
Ex vivo spiking study using plasma from 29 participants with haemophilia or VWD3.
Supplementation of plasma with KN057 at concentrations of 0-140.00 nM.
Assessment of coagulation responses using thrombin generation assay and dilute prothrombin time assay.
Increased peak thrombin and endogenous thrombin potential observed at concentrations of 1.12-5.60 nM, peaking at 28.00 nM.
Dose-dependent decrease in dilute prothrombin time across all participants with haemophilia or VWD3.
Pharmacodynamic response consistent across various haemophilia types and comparable in VWD3.

Ju et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark